OverweightPhase 1NCT07465965
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
A Phase 1 study testing Semaglutide Nasal Spray and Semaglutide Injection in people with Overweight and Obesity, run by Shanghai World Leader Pharmaceutical Co., Ltd. at 1 site in United States.
Trial summary
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Overweight, Obesity
- What is being tested?
- Semaglutide Nasal Spray and Semaglutide Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Mar 2026to 30 Aug 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female participants aged ≥18 years and ≤ 65 years.
- Body Mass Index (BMI) at screening between 27.0 and 35.0 kg/m² (inclusive).
- Weight change of no more than ±5% during the 3 months prior to screening with diet and exercise alone (self-reported).
- Participants (including males) must have no plans for conception during the study and within 3 months after the last administration, and must agree to use effective contraceptive methods and refrain from donating sperm or eggs during this period.
- Negative anti-HIV antibody test result at screening.
- Participants must fully understand the trial objectives, nature, procedures, and potential adverse reactions, voluntarily participate, be able to communicate well with the investigators, comply with all study requirements, and sign the informed consent form before any study procedures begin.
Who cannot join
- Diagnosis of type 1, type 2, or other forms of diabetes mellitus.
- Prior diagnosis of obesity caused by monogenic mutations or other medical conditions, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidism-related obesity, Cushing's syndrome, insulinoma, acromegaly, or hypogonadism.
- Prior history of bariatric surgery (excluding participants who had liposuction, abdominoplasty, intragastric balloon removal, or duodenal-jejunal bypass sleeve removal >1 year prior), or plan to undergo bariatric surgery or use weight-loss devices during the study.
- Use of any of the following treatments within 3 months prior to screening:
- Approved or unapproved anti-obesity medications (e.g., liraglutide, semaglutide, benaglutide, tirzepatide, orlistat, phentermine/topiramate, naltrexone/bupropion), or herbal supplements, health products, meal replacements, or weight-loss capsules that may affect body weight;
- Any glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1 related multi-agonists (e.g., GLP-1/glucose-dependent insulinotropic polypeptide [GIP] dual agonists, GLP-1/glucagon [GCG] dual agonists, GLP-1/GIP/GCG triple agonists), or combination preparations containing GLP-1 receptor agonists;
Show all 45Show fewer
- Any antidiabetic medications (e.g., odium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, metformin, alpha-glucosidase inhibitors, insulin);
- Any other treatments known to affect body weight (e.g., cause weight loss or weight gain), including:
- Systemic corticosteroid therapy (intravenous or oral) for >1 week
- Tricyclic antidepressants (e.g., imipramine, amitriptyline, doxepin)
- Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine)
- Antipsychotics/antiepileptics (e.g., imipramine, amitriptyline, mirtazapine, phenelzine, chlorpromazine HCl, clozapine, olanzapine, valproate derivatives, lithium preparations, thioridazine)
- Antihistamines (e.g., cyproheptadine, ketotifen, astemizole).
- Any investigational drugs, vaccines, or medical devices.
- Laboratory abnormalities at screening meeting any of the following:
- Glycated hemoglobin (HbA1c) ≥6.5% or fasting glucose ≥7.0 mmol/L;
- Uncontrolled hypertension, systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg;
- Thyroid-stimulating hormone (TSH) >4.2 or <0.27 mIU/L;
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5 × upper limit of normal (ULN), or total bilirubin ≥1.5 × ULN;
- Fasting triglycerides >3.42 mmol/L;
- Serum amylase or lipase ≥1.5×ULN;
- Calcitonin > ULN;
- Estimated glomerular filtration rate (eGFR) ≤80 mL/min/1.73 m²;
- Clinically significant ECG findings: HR <40 or >100 bpm, second- or third- degree atrioventricular (AV) block, long QT syndrome, QTcF >450 ms (male) or >470 ms (female), left bundle branch block (LBBB), complete right bundle branch block (RBBB), Wolff-Parkinson-White (WPW) syndrome, or other clinically significant arrhythmias (e.g., paroxysmal supraventricular tachycardia (SVT), atrial flutter/fibrillation, ventricular flutter or fibrillation, sick sinus syndrome) deemed unsuitable by the investigator.
- History of acute or chronic pancreatitis, or symptomatic gallbladder disease (except cholecystectomy).
- Participants with clinically significant abnormalities during nasal examination (including external nose and nasal cavity inspection) as determined by the investigator at screening.
- Nasal or sinus surgery or nasal trauma within 3 months prior to screening, not fully healed.
- Presence of nasal mucosal erosion, septal ulceration/perforation, or other nasal conditions (e.g., acute or chronic sinusitis, drug-induced rhinitis, allergic rhinitis, nasal polyps) that may affect intranasal drug deposition, as determined by the investigator.
- Participants with extensive scars or large tattoos on the abdomen, thighs, or upper arms that may interfere with drug administration.
- History of thyroid disease or abnormal thyroid function requiring treatment, deemed clinically significant.
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
- Any malignancy diagnosed within 5 years (except cured basal cell carcinoma, cervical carcinoma in situ, localized prostate cancer post-surgery, or ductal carcinoma in situ post-surgery).
- History of major cardiovascular or cerebrovascular events: a) MI, PCI/CABG, valvular surgery, clinically significant arrhythmias requiring treatment, unstable angina, TIA, stroke within 6 months prior to screening, b) NYHA Class III-IV heart failure.
- Clinically significant gastrointestinal (GI) diseases at screening or within the screening period: pyloric obstruction, ileus, delayed gastric emptying, inflammatory bowel disease (IBD), gastroparesis, gastroesophageal reflux disease (GERD), active peptic ulcer.
- Participants positive for hepatitis B surface antigen anti-hepatitis C virus antibody, or RPR at screening;
- Participants with upper respiratory tract infection occurring within 7 days before administration.
- Major depressive disorder or other severe psychiatric illness (e.g., schizophrenia, schizoaffective disorder, paranoid psychosis, bipolar disorder, epilepsy-related psychosis, intellectual disability with psychiatric symptoms) within 2 years before screening, or any history of self-harm or suicidal behavior, or participants with any suicidal ideation of type 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or type 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS.
- Blood donation within 3 months or total blood loss ≥400 mL within 6 months (excluding menstruation) prior to screening; planned donation within 3 months post-study.
- History of vasovagal syncope or intolerance to venipuncture/IV cannulation.
- Participants with a history of hypersensitivity or known/suspected allergy to GLP-1 receptor agonists or any excipients in the study drug formulation.
- History of alcohol abuse within 1 year prior to screening through check-in, defined as an average consumption >14 units/week (1 unit = 360 mL beer, 45 mL 40% spirits, or 150 mL wine); unwilling to abstain from alcohol use during study, or a positive breath alcohol test (>0.0 mg/100 mL).
- Smoking >5 cigarettes/day within 3 months prior to screening, or unwilling to abstain during study.
- History of substance abuse (including non-medical use of narcotics or psychotropic substances) within 1 year prior to screening through check-in; Positive drug screening test for: morphine, methamphetamine ("ice"), 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"), tetrahydrocannabinol (THC, cannabis), etc.
- Female Participants who are pregnant or breastfeeding, or with positive serum pregnancy test results at screening, or positive urine pregnancy test at check-in (Day -1);
- Any other condition deemed by the investigator to render the participant unsuitable for participation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Frontage Clinical Services, Inc.
Secaucus, New Jersey, 07094
12014167766
About this study
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic (PK) of Single-dose Administration of Semaglutide Nasal Spray (WL1006) in Adult Overweight or Obese Participants
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
- Conditions
- Overweight, Obesity
- Being tested
- Semaglutide Nasal Spray, Placebo, Semaglutide Injection
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Semaglutide Nasal SprayDrug
WL1006
PlaceboDrug
WL1006
Semaglutide InjectionDrug
Wegovy®
| Study group | Role | What they receive |
|---|---|---|
| Cohort A0 : Semaglutide Nasal Spray | Experimental | Not described Receives: Drug: Semaglutide Nasal Spray |
| Cohort A1: Semaglutide nasal spray and placebo | Experimental | Not described Receives: Drug: Semaglutide Nasal Spray; Drug: Placebo |
| Cohort A2:Semaglutide nasal spray and placebo | Experimental | Not described Receives: Drug: Semaglutide Nasal Spray; Drug: Placebo |
| Cohort A3: Semaglutide injection | Active comparator | Not described Receives: Drug: Semaglutide Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum Plasma Concentration (Cmax)
Measured: Day 1 to Day 36 after administration
Time to maximum concentration(Tmax)
Measured: Day 1 to Day 36 after administration
Area under the concentration-time curve from time 0 to time t (AUC0-t)
Measured: Day 1 to Day 36 after administration
Area under the concentration-time curve from time 0 to infinity(AUC0-∞)
Measured: Day 1 to Day 36 after administration
Percentage of AUC extrapolated(AUC%Extrap)
Measured: Day 1 to Day 36 after administration
Elimination half-life / Terminal half-life(t1/2)
Measured: Day 1 to Day 36 after administration
Apparent volume of distribution during terminal phase, adjusted for bioavailability (Vz/F)
Measured: Day 1 to Day 36 after administration
Apparent clearance, adjusted for bioavailability(CL/F)
Measured: Day 1 to Day 36 after administration
Terminal elimination rate constant(λz)
Measured: Day 1 to Day 36 after administration
Absolute bioavailability(F)
Measured: Day 1 to Day 36 after administration
Incidence and severity of treatment emergent adverse events (TEAEs)
Measured: Day 1 to Day 36 after administration
12-Lead-ECGs(Electrocardiograms )
Measured: Day 1 to Day 36 after administration
Temperature
Measured: Day 1 to Day 36 after administration
Pulse
Measured: Day 1 to Day 36 after administration
Respiratory rate
Measured: Day 1 to Day 36 after administration
Blood pressure
Measured: Day 1 to Day 36 after administration
Urinalysis
Measured: Day 1 to Day 36 after administration
Blood biochemistry
Alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, γ-glutamyl transferase, alkaline phosphatase, total protein, albumin, urea, uric acid, creatinine, calcium, chloride, potassium, sodium, phosphorus, total cholesterol, triglycerides, fasting blood glucose, creatine kinase, lactate dehydrogenase, amylase, lipase.
Measured: Day 1 to Day 36 after administration
Thyroid function
Thyroid-stimulating hormone, total tri-iodothyronine, total thyroxine, free tri-iodothyronine, free thyroxine
Measured: Day 1 to Day 36 after administration
Virology test
Measured: Day 1 to Day 36 after administration
Urine pregnancy test
Measured: Day 1 to Day 36 after administration
Physical examination, includes: head, ears, eyes, nose and throat, skin, lymph nodes, neck, chest, abdomen, heart, cardiovascular, musculoskeletal system/extremities, neurological system and body weight.
Measured: Day 1 to Day 4 after administration
Hemoglobin
Measured: Day 1 to Day 36 after administration
Hematocrit
Measured: Day 1 to Day 36 after administration
Red blood cell count
Measured: Day 1 to day 36
White blood cell count
Measured: Day 1 to day36
Platelet count
Measured: Day 1 to day 36
Neutrophil percentage
Measured: day 1 to day 36
Eosinophil percentage
Measured: day 1 to day 36
Basophil percentage
Measured: day 1 to day 36
Monocyte percentage
Measured: day 1 to day 36
Lymphocyte percentage
Measured: day 1 to day 36
Activated partial thromboplastin time
Measured: Day 1 to day 36
Prothrombin time
Measured: day 1 to day 36
Fibrinogen
Measured: day 1 to day 36
Thrombin time
Measured: day 1 to day 36
Secondary outcomes (4)
Positive rate of Anti-Drug Antibody (ADA)
Measured: Day 1 to Day 29 after administration
Titer of Anti-Drug Antibody (ADA)
Measured: Day 1 to Day 29 after administration
Positive rate of Neutralizing antibody (Nab)
if ADA is positive
Measured: Day 1 to Day 29 after administration
Titer of Neutralizing antibody (Nab)
if ADA is positive
Measured: Day 1 to Day 29 after administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2026
- Study start2 Mar 2026
- Primary completion21 Aug 2026 (estimated)
- Study completion30 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai World Leader Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07465965
- Sponsor's protocol ID
- WL1006-US-I-01
- Status last verified
- Mar 2026
- First submitted
- 28 Jan 2026
- Last updated
- 12 Mar 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic (PK) of Single-dose Administration of Semaglutide Nasal Spray (WL1006) in Adult Overweight or Obese Participants
- ClinicalTrials.gov ID
- NCT07465965
- Acronym / sponsor ID
- WL1006-US-I-01
- Conditions
- Overweight, Obesity
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Shanghai World Leader Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 2 Mar 2026 (actual)
- Primary completion
- 21 Aug 2026 (estimated)
- Study completion
- 30 Aug 2026 (estimated)
- First posted
- 12 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Cohort A0 : Semaglutide Nasal Spray | Experimental | Drug: Semaglutide Nasal Spray |
| Cohort A1: Semaglutide nasal spray and placebo | Experimental | Drug: Semaglutide Nasal Spray, Drug: Placebo |
| Cohort A2:Semaglutide nasal spray and placebo | Experimental | Drug: Semaglutide Nasal Spray, Drug: Placebo |
| Cohort A3: Semaglutide injection | Active comparator | Drug: Semaglutide Injection |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Male or female participants aged ≥18 years and ≤ 65 years.
- Body Mass Index (BMI) at screening between 27.0 and 35.0 kg/m² (inclusive).
- Weight change of no more than ±5% during the 3 months prior to screening with diet and exercise alone (self-reported).
- Participants (including males) must have no plans for conception during the study and within 3 months after the last administration, and must agree to use effective contraceptive methods and refrain from donating sperm or eggs during this period.
- Negative anti-HIV antibody test result at screening.
Key exclusion criteria (45 listed)
- Diagnosis of type 1, type 2, or other forms of diabetes mellitus.
- Prior diagnosis of obesity caused by monogenic mutations or other medical conditions, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidism-related obesity, Cushing's syndrome, insulinoma, acromegaly, or hypogonadism.
- Prior history of bariatric surgery (excluding participants who had liposuction, abdominoplasty, intragastric balloon removal, or duodenal-jejunal bypass sleeve removal >1 year prior), or plan to undergo bariatric surgery or use weight-loss devices during the study.
- Use of any of the following treatments within 3 months prior to screening:
- Laboratory abnormalities at screening meeting any of the following:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Semaglutide Nasal SprayWL1006 | Drug | Cohort A0 : Semaglutide Nasal Spray, Cohort A1: Semaglutide nasal spray and placebo, Cohort A2:Semaglutide nasal spray and placebo |
| PlaceboWL1006 | Drug | Cohort A1: Semaglutide nasal spray and placebo, Cohort A2:Semaglutide nasal spray and placebo |
| Semaglutide InjectionWegovy® | Drug | Cohort A3: Semaglutide injection |
Primary outcome
Maximum Plasma Concentration (Cmax)
Time frame: Day 1 to Day 36 after administration
Time to maximum concentration(Tmax)
Time frame: Day 1 to Day 36 after administration
Area under the concentration-time curve from time 0 to time t (AUC0-t)
Time frame: Day 1 to Day 36 after administration
Area under the concentration-time curve from time 0 to infinity(AUC0-∞)
Time frame: Day 1 to Day 36 after administration
Percentage of AUC extrapolated(AUC%Extrap)
Time frame: Day 1 to Day 36 after administration
Elimination half-life / Terminal half-life(t1/2)
Time frame: Day 1 to Day 36 after administration
Apparent volume of distribution during terminal phase, adjusted for bioavailability (Vz/F)
Time frame: Day 1 to Day 36 after administration
Apparent clearance, adjusted for bioavailability(CL/F)
Time frame: Day 1 to Day 36 after administration
Terminal elimination rate constant(λz)
Time frame: Day 1 to Day 36 after administration
Absolute bioavailability(F)
Time frame: Day 1 to Day 36 after administration
Incidence and severity of treatment emergent adverse events (TEAEs)
Time frame: Day 1 to Day 36 after administration
12-Lead-ECGs(Electrocardiograms )
Time frame: Day 1 to Day 36 after administration
Temperature
Time frame: Day 1 to Day 36 after administration
Pulse
Time frame: Day 1 to Day 36 after administration
Respiratory rate
Time frame: Day 1 to Day 36 after administration
Blood pressure
Time frame: Day 1 to Day 36 after administration
Urinalysis
Time frame: Day 1 to Day 36 after administration
Blood biochemistry
Time frame: Day 1 to Day 36 after administration
Alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, γ-glutamyl transferase, alkaline phosphatase, total protein, albumin, urea, uric acid, creatinine, calcium, chloride, potassium, sodium, phosphorus, total cholesterol, triglycerides, fasting blood glucose, creatine kinase, lactate dehydrogenase, amylase, lipase.
Thyroid function
Time frame: Day 1 to Day 36 after administration
Thyroid-stimulating hormone, total tri-iodothyronine, total thyroxine, free tri-iodothyronine, free thyroxine
Virology test
Time frame: Day 1 to Day 36 after administration
Urine pregnancy test
Time frame: Day 1 to Day 36 after administration
Physical examination, includes: head, ears, eyes, nose and throat, skin, lymph nodes, neck, chest, abdomen, heart, cardiovascular, musculoskeletal system/extremities, neurological system and body weight.
Time frame: Day 1 to Day 4 after administration
Hemoglobin
Time frame: Day 1 to Day 36 after administration
Hematocrit
Time frame: Day 1 to Day 36 after administration
Red blood cell count
Time frame: Day 1 to day 36
White blood cell count
Time frame: Day 1 to day36
Platelet count
Time frame: Day 1 to day 36
Neutrophil percentage
Time frame: day 1 to day 36
Eosinophil percentage
Time frame: day 1 to day 36
Basophil percentage
Time frame: day 1 to day 36
Monocyte percentage
Time frame: day 1 to day 36
Lymphocyte percentage
Time frame: day 1 to day 36
Activated partial thromboplastin time
Time frame: Day 1 to day 36
Prothrombin time
Time frame: day 1 to day 36
Fibrinogen
Time frame: day 1 to day 36
Thrombin time
Time frame: day 1 to day 36
4 secondary outcomes
Positive rate of Anti-Drug Antibody (ADA)
Time frame: Day 1 to Day 29 after administration
Titer of Anti-Drug Antibody (ADA)
Time frame: Day 1 to Day 29 after administration
Positive rate of Neutralizing antibody (Nab)
Time frame: Day 1 to Day 29 after administration
Titer of Neutralizing antibody (Nab)
Time frame: Day 1 to Day 29 after administration
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Semaglutide Nasal Spray and Semaglutide Injection in people with Overweight and Obesity, run by Shanghai World Leader Pharmaceutical Co., Ltd. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 45 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Guiyi Huang, Master (0086-18640027113, huangguiyi@worldleadertdds.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum Plasma Concentration (Cmax) (time frame: Day 1 to Day 36 after administration). The study lists 36 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.